Form D · Biotechnology

StrideBio, Inc.

Durham, NC · CIK 0001708278

Offering snapshot reported Mar 26, 2021 · SEC filing

Reported sold
$48.9M
Offering amount: $81.5M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 11, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 26, 2021Initial$48,917,942No comparison17SEC filing
Jun 18, 2018Initial$7,739,081No comparison12SEC filing
Jun 5, 2017Initial$1,000,000No comparison3SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-393667
Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.

Source: Form D, filed Mar 26, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mavis Abjandje Mc Kenna Director
Mavis Agbandje Mc Kenna Director, Promoter
Aravind Asokan Director
Mike Dial Director
Shaan Gandhi Director
Karen Hong Director
Robert Hughes Executive
Michael Martin Director
Maritza Mc Intyre Executive
William Monteith Executive
Stewart Parker Director
Patrick Ritschel Director, Executive, Promoter
Sapan Shah Director, Executive
Richard Smith Executive
Clay Thorp Director
Erica Whittaker Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5 Laboratory Drive, Suite 1200
Durham, NC, 27709